|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PREPL |
Gene summary for PREPL |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PREPL | Gene ID | 9581 |
| Gene name | prolyl endopeptidase like | |
| Gene Alias | CMS22 | |
| Cytomap | 2p21 | |
| Gene Type | protein-coding | GO ID | GO:0001505 | UniProtAcc | Q4J6C6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9581 | PREPL | LZE2T | Human | Esophagus | ESCC | 3.47e-03 | 4.69e-01 | 0.082 |
| 9581 | PREPL | LZE4T | Human | Esophagus | ESCC | 1.50e-08 | 2.25e-01 | 0.0811 |
| 9581 | PREPL | LZE7T | Human | Esophagus | ESCC | 6.37e-07 | 3.21e-01 | 0.0667 |
| 9581 | PREPL | LZE22T | Human | Esophagus | ESCC | 8.56e-03 | 2.34e-01 | 0.068 |
| 9581 | PREPL | LZE24T | Human | Esophagus | ESCC | 9.18e-14 | 3.15e-01 | 0.0596 |
| 9581 | PREPL | LZE6T | Human | Esophagus | ESCC | 5.76e-05 | 1.58e-01 | 0.0845 |
| 9581 | PREPL | P2T-E | Human | Esophagus | ESCC | 8.69e-32 | 5.06e-01 | 0.1177 |
| 9581 | PREPL | P4T-E | Human | Esophagus | ESCC | 1.64e-17 | 2.94e-01 | 0.1323 |
| 9581 | PREPL | P5T-E | Human | Esophagus | ESCC | 3.35e-10 | 1.17e-01 | 0.1327 |
| 9581 | PREPL | P8T-E | Human | Esophagus | ESCC | 1.43e-08 | 2.19e-01 | 0.0889 |
| 9581 | PREPL | P9T-E | Human | Esophagus | ESCC | 1.72e-14 | 1.50e-01 | 0.1131 |
| 9581 | PREPL | P10T-E | Human | Esophagus | ESCC | 2.65e-26 | 4.48e-01 | 0.116 |
| 9581 | PREPL | P11T-E | Human | Esophagus | ESCC | 3.75e-11 | 3.69e-01 | 0.1426 |
| 9581 | PREPL | P12T-E | Human | Esophagus | ESCC | 3.00e-13 | 2.59e-01 | 0.1122 |
| 9581 | PREPL | P15T-E | Human | Esophagus | ESCC | 1.19e-11 | 2.80e-01 | 0.1149 |
| 9581 | PREPL | P16T-E | Human | Esophagus | ESCC | 2.69e-34 | 4.89e-01 | 0.1153 |
| 9581 | PREPL | P17T-E | Human | Esophagus | ESCC | 7.03e-08 | 2.39e-01 | 0.1278 |
| 9581 | PREPL | P19T-E | Human | Esophagus | ESCC | 4.60e-11 | 5.00e-01 | 0.1662 |
| 9581 | PREPL | P20T-E | Human | Esophagus | ESCC | 1.10e-13 | 3.23e-01 | 0.1124 |
| 9581 | PREPL | P21T-E | Human | Esophagus | ESCC | 7.07e-11 | 1.96e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:0072659110 | Esophagus | ESCC | protein localization to plasma membrane | 193/8552 | 284/18723 | 1.95e-14 | 1.03e-12 | 193 |
| GO:001648210 | Esophagus | ESCC | cytosolic transport | 124/8552 | 168/18723 | 9.69e-14 | 4.69e-12 | 124 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:000689215 | Esophagus | ESCC | post-Golgi vesicle-mediated transport | 82/8552 | 104/18723 | 4.00e-12 | 1.55e-10 | 82 |
| GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
| GO:000689315 | Esophagus | ESCC | Golgi to plasma membrane transport | 48/8552 | 60/18723 | 5.11e-08 | 9.16e-07 | 48 |
| GO:004300114 | Esophagus | ESCC | Golgi to plasma membrane protein transport | 34/8552 | 40/18723 | 3.00e-07 | 4.27e-06 | 34 |
| GO:00421477 | Esophagus | ESCC | retrograde transport, endosome to Golgi | 63/8552 | 91/18723 | 4.58e-06 | 4.87e-05 | 63 |
| GO:006195114 | Esophagus | ESCC | establishment of protein localization to plasma membrane | 44/8552 | 60/18723 | 1.25e-05 | 1.15e-04 | 44 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:199077811 | Liver | Cirrhotic | protein localization to cell periphery | 135/4634 | 333/18723 | 1.18e-10 | 6.21e-09 | 135 |
| GO:007265911 | Liver | Cirrhotic | protein localization to plasma membrane | 119/4634 | 284/18723 | 1.30e-10 | 6.80e-09 | 119 |
| GO:004300111 | Liver | Cirrhotic | Golgi to plasma membrane protein transport | 27/4634 | 40/18723 | 1.43e-08 | 5.36e-07 | 27 |
| GO:001648211 | Liver | Cirrhotic | cytosolic transport | 74/4634 | 168/18723 | 3.34e-08 | 1.12e-06 | 74 |
| GO:000689211 | Liver | Cirrhotic | post-Golgi vesicle-mediated transport | 51/4634 | 104/18723 | 7.12e-08 | 2.15e-06 | 51 |
| GO:001619711 | Liver | Cirrhotic | endosomal transport | 93/4634 | 230/18723 | 1.01e-07 | 2.93e-06 | 93 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PREPL | SNV | Missense_Mutation | c.1303G>C | p.Asp435His | p.D435H | Q4J6C6 | protein_coding | tolerated(0.15) | benign(0.04) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| PREPL | SNV | Missense_Mutation | rs749766335 | c.961G>A | p.Glu321Lys | p.E321K | Q4J6C6 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PREPL | SNV | Missense_Mutation | rs759701052 | c.241G>A | p.Glu81Lys | p.E81K | Q4J6C6 | protein_coding | tolerated(0.35) | benign(0.028) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PREPL | SNV | Missense_Mutation | c.2048N>T | p.Asp683Val | p.D683V | Q4J6C6 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| PREPL | SNV | Missense_Mutation | c.697N>C | p.Ala233Pro | p.A233P | Q4J6C6 | protein_coding | tolerated(0.14) | possibly_damaging(0.805) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| PREPL | SNV | Missense_Mutation | c.988N>C | p.Asp330His | p.D330H | Q4J6C6 | protein_coding | tolerated(0.13) | possibly_damaging(0.906) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PREPL | SNV | Missense_Mutation | c.1477N>C | p.Glu493Gln | p.E493Q | Q4J6C6 | protein_coding | deleterious(0.04) | probably_damaging(0.989) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| PREPL | SNV | Missense_Mutation | c.461N>G | p.Asp154Gly | p.D154G | Q4J6C6 | protein_coding | tolerated(0.6) | benign(0) | TCGA-E2-A1B5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| PREPL | insertion | Nonsense_Mutation | novel | c.542_543insCAAATTATTATCTAGAATAAATTTTTACACGTAAGT | p.Ala181_Ser182insLysLeuLeuSerArgIleAsnPheTyrThrTerVal | p.A181_S182insKLLSRINFYT*V | Q4J6C6 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| PREPL | insertion | Frame_Shift_Ins | novel | c.1241_1242insATTTA | p.Pro415PhefsTer34 | p.P415Ffs*34 | Q4J6C6 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |